In Brief: Cytogen's OncoScint CR/OV
Executive Summary
Cytogen's OncoScint CR/OV: FDA list of important biologics approved in 1994 incorrectly listed the imaging agent, approved in December 1992 for the diagnosis of colorectal and ovarian cancer, instead Mallinckrodt's pentetreotide radiolabeled with indium In-111 imaging agent OctreoScan. The NDA for OctreoScan was approved June 2, 1994...